Relationship of timing of agonist administration in the cycle phase to the ovarian response to gonadotropins in the long down-regulation protocols for assisted reproductive technologies

Fertil Steril. 1996 Jan;65(1):114-21. doi: 10.1016/s0015-0282(16)58037-6.

Abstract

Objective: To assess whether the ovarian response to exogenous gonadotropins and cycle performance is affected by different timing of an agonist administration in long down-regulation protocols.

Design: An agonist was administered irrespective of cycle phase, with exogenous gonadotropin beginning 15 days later.

Patients: Five hundred fifty-seven normovulatory infertile patients, aged < or = 38 years, were classified into seven study groups, depending on the phase of the cycle in which agonist was started.

Main outcome measures: Endocrine profile, amount of exogenous stimulation, occurrence of ovarian cysts, mean number of oocytes recovered and embryos transferred, pregnancy rate, implantation rate, and live-birth rate of the seven groups.

Results: The ovarian response of the groups did not show any statistically significant differences in relation to the initiation of the agonist. The only effect was a different incidence of ovarian cyst formation, but this phenomenon did not affect cycle performance. The pregnancy, implantation, and live-birth rates showed differences that did not reach statistical significance.

Conclusion: Agonists initiation can be programmed in advance irrespective of the phase of the cycle. This approach can be of help for the logistics of assisted reproduction programs.

MeSH terms

  • Adult
  • Buserelin / pharmacology*
  • Embryo Transfer*
  • Female
  • Fertilization in Vitro*
  • Follicle Stimulating Hormone / pharmacology
  • Humans
  • Menotropins / pharmacology
  • Ovarian Cysts / etiology
  • Ovary / drug effects*
  • Pregnancy
  • Time Factors

Substances

  • Menotropins
  • Follicle Stimulating Hormone
  • Buserelin